Sangamo Stock Based Compensation vs Investments Analysis

SGMO Stock  USD 2.64  0.01  0.38%   
Sangamo Therapeutics financial indicator trend analysis is much more than just breaking down Sangamo Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sangamo Therapeutics is a good investment. Please check the relationship between Sangamo Therapeutics Stock Based Compensation and its Investments accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

Stock Based Compensation vs Investments

JavaScript chart by amCharts 3.21.152014201620182020202220246M8M10M12M14M16M18M20M22M24M26M28M30M32M -250M-200M-150M-100M-50M050M100M150M200M250M
JavaScript chart by amCharts 3.21.15Stock Based Compensationtotal: 231.6MInvestmentstotal: 178.7M

Stock Based Compensation vs Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sangamo Therapeutics Stock Based Compensation account and Investments. At this time, the significance of the direction appears to have fragmental relationship.
Stock Based CompensationInvestmentsDiversified AwayStock Based CompensationInvestmentsDiversified Away100%
The correlation between Sangamo Therapeutics' Stock Based Compensation and Investments is 0.48. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Investments in the same time period over historical financial statements of Sangamo Therapeutics, assuming nothing else is changed. The correlation between historical values of Sangamo Therapeutics' Stock Based Compensation and Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Sangamo Therapeutics are associated (or correlated) with its Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Investments has no effect on the direction of Stock Based Compensation i.e., Sangamo Therapeutics' Stock Based Compensation and Investments go up and down completely randomly.

Correlation Coefficient

0.48
Relationship DirectionPositive 
Relationship StrengthWeak

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Investments

Securities or assets acquired for generating income or appreciating in value, not used in daily operations.
Most indicators from Sangamo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.As of the 27th of December 2024, Selling General Administrative is likely to grow to about 64.2 M, though Tax Provision is likely to grow to (4.3 M).
 2021 2022 2023 2024 (projected)
Reconciled Depreciation17.6M20.6M24.6M14.1M
Net Interest Income5.3M9.4M13.3M7.9M

Sangamo Therapeutics fundamental ratios Correlations

0.97-0.40.890.530.630.970.80.790.950.910.420.890.940.320.960.410.060.890.970.750.970.03-0.780.70.51
0.97-0.310.810.460.560.890.730.70.860.840.320.830.880.210.960.54-0.060.910.90.650.97-0.1-0.740.560.42
-0.4-0.31-0.41-0.98-0.96-0.48-0.79-0.38-0.56-0.6-0.87-0.46-0.51-0.96-0.220.0-0.13-0.11-0.45-0.84-0.32-0.220.19-0.7-0.86
0.890.81-0.410.490.580.920.80.640.930.940.520.830.950.330.790.310.230.690.90.80.790.19-0.720.860.46
0.530.46-0.980.490.990.580.840.470.650.670.860.560.610.930.370.080.060.260.560.880.460.14-0.290.730.86
0.630.56-0.960.580.990.660.890.520.730.760.850.640.690.90.460.150.090.350.640.920.550.16-0.370.770.87
0.970.89-0.480.920.580.660.840.830.990.930.510.890.950.420.920.260.180.821.00.810.920.16-0.780.810.57
0.80.73-0.790.80.840.890.840.610.880.930.690.780.870.750.650.350.220.540.820.960.710.25-0.530.790.8
0.790.7-0.380.640.470.520.830.610.80.660.440.610.660.360.810.060.160.830.850.560.820.16-0.510.590.41
0.950.86-0.560.930.650.730.990.880.80.950.590.90.960.50.880.220.180.770.970.860.880.17-0.770.860.63
0.910.84-0.60.940.670.760.930.930.660.950.610.870.970.530.780.390.240.660.910.920.80.23-0.690.840.67
0.420.32-0.870.520.860.850.510.690.440.590.610.390.560.820.23-0.020.220.150.480.810.310.28-0.150.810.69
0.890.83-0.460.830.560.640.890.780.610.90.870.390.880.410.830.170.080.670.880.760.830.07-0.940.730.62
0.940.88-0.510.950.610.690.950.870.660.960.970.560.880.440.830.40.20.70.940.870.840.18-0.740.830.58
0.320.21-0.960.330.930.90.420.750.360.50.530.820.410.440.14-0.130.30.030.410.810.240.4-0.140.650.9
0.960.96-0.220.790.370.460.920.650.810.880.780.230.830.830.140.37-0.050.960.920.560.98-0.09-0.780.550.33
0.410.540.00.310.080.150.260.350.060.220.39-0.020.170.4-0.130.37-0.10.410.270.230.39-0.13-0.06-0.02-0.04
0.06-0.06-0.130.230.060.090.180.220.160.180.240.220.080.20.3-0.05-0.1-0.090.190.3-0.020.99-0.030.310.24
0.890.91-0.110.690.260.350.820.540.830.770.660.150.670.70.030.960.41-0.090.830.420.95-0.14-0.620.40.23
0.970.9-0.450.90.560.641.00.820.850.970.910.480.880.940.410.920.270.190.830.790.930.16-0.770.780.55
0.750.65-0.840.80.880.920.810.960.560.860.920.810.760.870.810.560.230.30.420.790.630.34-0.530.890.84
0.970.97-0.320.790.460.550.920.710.820.880.80.310.830.840.240.980.39-0.020.950.930.63-0.05-0.750.570.44
0.03-0.1-0.220.190.140.160.160.250.160.170.230.280.070.180.4-0.09-0.130.99-0.140.160.34-0.050.010.320.31
-0.78-0.740.19-0.72-0.29-0.37-0.78-0.53-0.51-0.77-0.69-0.15-0.94-0.74-0.14-0.78-0.06-0.03-0.62-0.77-0.53-0.750.01-0.57-0.4
0.70.56-0.70.860.730.770.810.790.590.860.840.810.730.830.650.55-0.020.310.40.780.890.570.32-0.570.63
0.510.42-0.860.460.860.870.570.80.410.630.670.690.620.580.90.33-0.040.240.230.550.840.440.31-0.40.63
Click cells to compare fundamentals

Sangamo Therapeutics Account Relationship Matchups

Sangamo Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets637.5M938.6M721.9M562.5M165.3M218.1M
Total Stockholder Equity432.7M497.4M375.3M295.0M82.9M144.6M
Retained Earnings(657.0M)(778.0M)(956.3M)(1.1B)(1.4B)(1.3B)
Other Assets10.6M15.1M16.8M18.5M1.00.95
Common Stock Shares Outstanding112.1M134.4M144.6M154.3M174.4M183.2M
Liabilities And Stockholders Equity637.5M938.6M721.9M562.5M165.3M218.1M
Other Stockholder Equity1.1B1.3B1.3B1.5B1.5B1.6B
Total Liab204.8M441.2M346.6M267.6M82.4M73.5M
Short Long Term Debt Total44.4M42.1M48.1M43.1M38.1M30.0M
Other Current Liab21.3M127.3M28.4M33.4M27.9M14.0M
Total Current Liabilities69.9M143.5M127.9M111.7M47.7M34.0M
Property Plant And Equipment Net107.2M112.4M124.7M125.5M52.9M29.2M
Accounts Payable6.7M12.6M9.8M22.4M15.3M16.0M
Cash80.4M131.3M178.9M100.4M45.2M45.0M
Non Current Assets Total232.0M278.9M323.2M262.2M71.0M68.1M
Non Currrent Assets Other4.0M7.9M10.2M12.3M18.1M19.0M
Cash And Short Term Investments385.0M692.0M464.7M277.6M81.0M77.0M
Net Receivables37.6M6.3M6.4M4.5M1.3M1.3M
Common Stock Total Equity1.2M1.4M1.5M1.7M1.5M1.4M
Short Term Investments282.0M510.1M197.7M177.2M35.8M34.0M
Non Current Liabilities Total134.9M297.6M218.7M155.8M34.7M57.7M
Property Plant And Equipment Gross107.2M112.4M149.7M162.1M103.9M109.1M
Total Current Assets405.5M659.7M398.8M300.3M94.3M175.7M
Accumulated Other Comprehensive Income(2.4M)5.4M(4.0M)(8.4M)(4.6M)(4.4M)
Common Stock1.2M1.4M1.5M1.7M1.8M1.7M
Net Debt(36.0M)(89.2M)(130.8M)(57.3M)(7.1M)(7.5M)
Other Current Assets5.4M24.0M31.7M36.4M12M12.6M
Property Plant Equipment29.9M41.3M51.5M63.5M73.1M76.7M
Current Deferred Revenue38.7M96.6M85.7M51.8M59.5M62.5M
Intangible Assets53.2M58.1M53.8M50.7M58.3M61.3M
Other Liab93.7M259.2M174.6M116.9M134.4M141.1M
Net Tangible Assets340.1M397.3M281.9M206.7M237.7M227.0M
Retained Earnings Total Equity(657.0M)(778.0M)(956.3M)(1.1B)(1.0B)(982.0M)
Capital Surpluse1.1B1.3B1.3B1.5B1.7B873.1M
Inventory(22.5M)(50.5M)(88.2M)1.00.90.95
Deferred Long Term Liab6.6M7.2M6.6M6.3M7.2M9.3M

Pair Trading with Sangamo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Sangamo Stock

  0.77ME 23Andme HoldingPairCorr
  0.76DOMH Dominari HoldingsPairCorr
  0.74VINC Vincerx PharmaPairCorr
  0.68DTIL Precision BioSciencesPairCorr
  0.64VALN Valneva SE ADRPairCorr
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.24)
Revenue Per Share
0.066
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.58)
Return On Equity
(1.94)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

FATE
Fate Therapeutics
1.61  -0.01  -0.62 
KPTI
Karyopharm Therapeutics
0.70  0.10  16.67 
CRBU
Caribou Biosciences
1.67  -0.03  -1.76 
News Freq…Investor S…